Corvus Pharmaceuticals Discontinues Phase III Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Corvus Pharmaceuticals, Inc. announced that it has discontinued its Phase III study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering serious infection and hospitalizations.